Retinopathy of Prematurity among Very-Low-Birth-Weight Infants in Korea: Incidence, Treatment, and Risk Factors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, Jong Hee | - |
dc.contributor.author | Lee, Eun Hee | - |
dc.contributor.author | Kim, Ellen Ai-Rhan | - |
dc.date.accessioned | 2021-09-04T11:53:21Z | - |
dc.date.available | 2021-09-04T11:53:21Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-10 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92270 | - |
dc.description.abstract | This study was conducted to describe the incidence, risk factors, and current treatment status of retinopathy of prematurity (ROP) in very-low-birth-weight (VLBW) infants registered in the Korean Neonatal Network database. Medical records of 2,009 VLBW infants born between January 2013 and June 2014 who underwent examination by an ophthalmologist were reviewed. The total incidence of ROP was 34.1%. Of the patients, 11.6% showed ROP stage >= 3 and 11.5% received treatment of VLBW. Among all infants who received treatment of ROP, 63.6% underwent operation only; 16.9%, anti-vascular endothelial growth factor (anti-VEGF) treatment only; and 19.5%, both operation and anti-VEGF treatment. The mean gestational age (GA) and birth weight (BW) were significantly lower and the prevalence rates of respiratory distress syndrome, patent ductus arteriosus (PDA), invasive ventilator duration, and sepsis were significantly higher in the VLBW infants with ROP than in those without ROP. In the multivariable logistic regression analysis, PDA (odd ratio [OR], 2.1; 95% confidence interval [CI], 1.11-3.79) and invasive ventilator duration (OR, 1.0; 95% CI, 1.00-1.02) were significant risk factors of ROP and ROP stage >= 3. In conclusion, the high incidence of ROP is associated with low GA and BW, and attempt to reduce the aforementioned risk factors could reduce the incidence of ROP stage >= 3 in VLBW infants. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | NETHERLANDS | - |
dc.subject | POPULATION | - |
dc.subject | CHILDHOOD | - |
dc.subject | NETWORK | - |
dc.subject | CANADA | - |
dc.title | Retinopathy of Prematurity among Very-Low-Birth-Weight Infants in Korea: Incidence, Treatment, and Risk Factors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Eun Hee | - |
dc.identifier.doi | 10.3346/jkms.2015.30.S1.S88 | - |
dc.identifier.scopusid | 2-s2.0-84952948218 | - |
dc.identifier.wosid | 000365715000013 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.30, pp.S88 - S94 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 30 | - |
dc.citation.startPage | S88 | - |
dc.citation.endPage | S94 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | NETHERLANDS | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordPlus | CHILDHOOD | - |
dc.subject.keywordPlus | NETWORK | - |
dc.subject.keywordPlus | CANADA | - |
dc.subject.keywordAuthor | Retinopathy of Prematurity | - |
dc.subject.keywordAuthor | Infant | - |
dc.subject.keywordAuthor | Very-Low-Birth-Weight | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.